现代肿瘤医学
現代腫瘤醫學
현대종류의학
Journal of Modern Oncology
2015年
19期
2777-2781
,共5页
刘艳萍%曾爱屏%宋向群%周韶璋%于起涛
劉豔萍%曾愛屏%宋嚮群%週韶璋%于起濤
류염평%증애병%송향군%주소장%우기도
非小细胞肺癌%脑转移%肿瘤标志物%预后
非小細胞肺癌%腦轉移%腫瘤標誌物%預後
비소세포폐암%뇌전이%종류표지물%예후
non - small cell lung cancer%brain metastasis%serum tumors%prognosis
目的：探讨血清 CEA、CA125、CA153、CA199、CA724和 CYFRA21-1水平与晚期非小细胞肺癌（NSCLC）脑转移发生和预后的相关性。方法：回顾性分析我院2009年4月至2013年10月289例（非脑转移223例，脑转移66例）未进行过任何治疗的Ⅳ期 NSCLC 患者临床资料。结果：全组病例脑转移发生率为22.8％（66/289），66例脑转移的中位生存期为9.4个月，1年、2年生存率分别为37％、15％。高表达患者的血清 CEA 水平与脑转移发生相关，无脑转移和脑转移患者血清 CEA 中位数分别为6.8ng/ ml、16.0ng/ ml（P =0.001）。血清 CEA≤5ng/ ml 者比 CEA ＞5ng/ ml 者预后好，中位生存时间分别为15个月和8个月（ P =0.027）；与血清 CA125≤35ng/ ml 相比，血清 CA125＞35ng/ ml 预后差，两者中位生存时间分别为13个月和7个月（P =0.008）。多因素显示血清 CA125水平、是否放疗和性别是影响 NSCLC 脑转移生存预后的独立因素。结论：高表达的血清 CEA 水平可预测 NSCLC 脑转移发生；血清 CA125水平是影响 NSCLC 脑转移患者预后的独立因素。
目的：探討血清 CEA、CA125、CA153、CA199、CA724和 CYFRA21-1水平與晚期非小細胞肺癌（NSCLC）腦轉移髮生和預後的相關性。方法：迴顧性分析我院2009年4月至2013年10月289例（非腦轉移223例，腦轉移66例）未進行過任何治療的Ⅳ期 NSCLC 患者臨床資料。結果：全組病例腦轉移髮生率為22.8％（66/289），66例腦轉移的中位生存期為9.4箇月，1年、2年生存率分彆為37％、15％。高錶達患者的血清 CEA 水平與腦轉移髮生相關，無腦轉移和腦轉移患者血清 CEA 中位數分彆為6.8ng/ ml、16.0ng/ ml（P =0.001）。血清 CEA≤5ng/ ml 者比 CEA ＞5ng/ ml 者預後好，中位生存時間分彆為15箇月和8箇月（ P =0.027）；與血清 CA125≤35ng/ ml 相比，血清 CA125＞35ng/ ml 預後差，兩者中位生存時間分彆為13箇月和7箇月（P =0.008）。多因素顯示血清 CA125水平、是否放療和性彆是影響 NSCLC 腦轉移生存預後的獨立因素。結論：高錶達的血清 CEA 水平可預測 NSCLC 腦轉移髮生；血清 CA125水平是影響 NSCLC 腦轉移患者預後的獨立因素。
목적：탐토혈청 CEA、CA125、CA153、CA199、CA724화 CYFRA21-1수평여만기비소세포폐암（NSCLC）뇌전이발생화예후적상관성。방법：회고성분석아원2009년4월지2013년10월289례（비뇌전이223례，뇌전이66례）미진행과임하치료적Ⅳ기 NSCLC 환자림상자료。결과：전조병례뇌전이발생솔위22.8％（66/289），66례뇌전이적중위생존기위9.4개월，1년、2년생존솔분별위37％、15％。고표체환자적혈청 CEA 수평여뇌전이발생상관，무뇌전이화뇌전이환자혈청 CEA 중위수분별위6.8ng/ ml、16.0ng/ ml（P =0.001）。혈청 CEA≤5ng/ ml 자비 CEA ＞5ng/ ml 자예후호，중위생존시간분별위15개월화8개월（ P =0.027）；여혈청 CA125≤35ng/ ml 상비，혈청 CA125＞35ng/ ml 예후차，량자중위생존시간분별위13개월화7개월（P =0.008）。다인소현시혈청 CA125수평、시부방료화성별시영향 NSCLC 뇌전이생존예후적독립인소。결론：고표체적혈청 CEA 수평가예측 NSCLC 뇌전이발생；혈청 CA125수평시영향 NSCLC 뇌전이환자예후적독립인소。
Objective:To explore the relationship between serum tumor markers and brain metastasis in patients with advanced non - small cell lung cancer(NSCLC). Methods:The clinical data of 289 advanced NSCLC patients hospitalized from April 2009 to October 2013 were retrospectively analyzed. All the enrolled patients were newly diag-nosed NSCLC with stage Ⅳ and not received treatment previously. Of those patients,223 had no brain metastasis. The rest were diagnosed with brain metastasis. Results:The incidence of brain metastasis was 22. 8%(66 / 289),the medi-an survival time of patients with the brain metastasis was 9. 4 months. The 1 - year and 2 - year survival rates were 37% and 15% respectively. The serum level of carcinoembryonic antigen(CEA)was significantly different between no brain metastasis patients and those who had(P = 0. 001). The median value of CEA of patients with and without brain metastasis was 6. 8ng/ ml,16. 0ng/ ml respectively. Overall survival was significantly shorter among patients with elevated serum CEA(median survival 15 months vs. 8 months,P = 0. 027)or CA125(median survival 13 months vs. 7 months,P = 0. 008). In multivariate analysis,CA125,radiotherapy and sex were independent prognostic factors for brain metastasis(P < 0. 05). Conclusion:The high serum CEA level may be potentially used as an indicator to predict the probability of brain metastasis in patients with NSCLC. The high serum CA125 may be used as reference index of the prognosis of brain metastasis in patients with NSCLC.
